Sena-Esteves Miguel, Hampl Jürgen A, Camp Sara M, Breakefield Xandra O
Molecular Neurogenetics Unit and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
J Gene Med. 2002 May-Jun;4(3):229-39. doi: 10.1002/jgm.276.
A number of properties have relegated the use of Moloney murine leukemia virus (Mo-MLV)-based retrovirus vectors primarily to ex vivo protocols. Direct implantation of retrovirus producer cells can bypass some of the limitations, and in situ vector production may result in a large number of gene transfer events. However, the fibroblast nature of most retrovirus packaging cells does not provide for an effective distribution of vector producing foci in vivo, especially in the brain. Effective development of new retrovirus producer cells with enhanced biologic properties may require the testing of a large number of different cell types, and a quick and efficient method to generate them is needed.
Moloney murine leukemia virus (Mo-MLV) gag-pol and env genes and retrovirus vector sequences carrying lacZ were cloned into different minimal HSV/AAV hybrid amplicons. Helper virus-free amplicon vectors were used to co-infect glioma cells in culture. Titers and stability of retrovirus vector production were assessed.
Simultaneous infection of two glioma lines, Gli-36 (human) and J3T (dog), with both types of amplicon vectors, generated stable packaging populations that produced retrovirus titers of 0.5-1.2 x 10(5) and 3.1-7.1 x 10(3) tu/ml, respectively. Alternatively, when cells were first infected with retrovirus vectors followed by infection with HyRMOVAmpho amplicon vector, stable retrovirus packaging populations were obtained from Gli-36 and J3T cells producing retrovirus titers comparable to those obtained with a traditional retrovirus packaging cell line, Psi CRIPlacZ.
This amplicon vector system should facilitate generation of new types of retrovirus producer cells. Conversion of cells with migratory or tumor/tissue homing properties could result in expansion of the spatial distribution or targeting capacity, respectively, of gene delivery by retrovirus vectors in vivo.
许多特性使得基于莫洛尼鼠白血病病毒(Mo-MLV)的逆转录病毒载体主要应用于体外实验方案。直接植入逆转录病毒产生细胞可以绕过一些限制,原位载体生产可能会导致大量基因转移事件。然而,大多数逆转录病毒包装细胞的成纤维细胞性质无法在体内有效分布载体产生灶,尤其是在大脑中。有效开发具有增强生物学特性的新型逆转录病毒产生细胞可能需要测试大量不同的细胞类型,因此需要一种快速有效的方法来生成它们。
将莫洛尼鼠白血病病毒(Mo-MLV)的gag-pol和env基因以及携带lacZ的逆转录病毒载体序列克隆到不同的最小单纯疱疹病毒/腺相关病毒杂交扩增子中。使用无辅助病毒的扩增子载体共感染培养中的胶质瘤细胞。评估逆转录病毒载体生产的滴度和稳定性。
用两种类型的扩增子载体同时感染两种胶质瘤细胞系Gli-36(人)和J3T(犬),产生了稳定的包装群体,分别产生0.5 - 1.2×10⁵和3.1 - 7.1×10³转导单位/毫升的逆转录病毒滴度。或者,当细胞先用逆转录病毒载体感染,然后再用HyRMOVAmpho扩增子载体感染时,从Gli-36和J3T细胞中获得了稳定的逆转录病毒包装群体,其产生的逆转录病毒滴度与用传统逆转录病毒包装细胞系Psi CRIPlacZ获得的滴度相当。
这种扩增子载体系统应有助于新型逆转录病毒产生细胞的生成。具有迁移或肿瘤/组织归巢特性的细胞转化可能分别导致逆转录病毒载体在体内基因递送的空间分布扩大或靶向能力增强。